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Table: Correlations between STR methods and infarct size
Spearman
rank A vs B A vs C B vs C
STR p0.0007 p0.75 p0.06 p0.009
max STR p0.0026 p0.76 p0.10 p0.06
ST residual p0.0001 p0.28 p0.0001 p0.0001
max ST residual p0.0001 p0.005 p0.0001 p0.0003
new Q waves p0.0001 p0.0001 p0.0001 p0.056
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Background: The HEBE study is a multicenter trial, where 200 patients with large first
AMI treated with primary percutaneous coronary intervention were randomly assigned to
either intracoronary infusion of mononuclear bone marrow (BMMC) cells (n69),
mononuclear peripheral blood cells (PBMC) (n66), or standard therapy (n65). At 4
months, regional or global systolic myocardial function improved in all groups, with no
significant difference between groups. Here, we conducted a 2 year magnetic resonance
imaging (MRI) follow-up.
Methods: In addition to 3-5 days after AMI, 4 months, patients underwent MRI at 2 years
after myocardial infarction and mononuclear cell infusion. All MRI analyses were
performed in a core laboratory using a standardized protocol and blinded for treatment
assignment.
Results: The percentage of dysfunctional left ventricular (LV) segments that improved
during 2 years of follow-up, did not differ significantly between BMMC and control:
(45.026.3% in the BMMC group, and 52.322.6% in the control group (p0.14).
However, the percentage was significantly lower in the PBMC group, 42.520.7%,
p0.03. Furthermore, there was less increase in LVEDV for BMMC (3.516.9 mL/m2)
compared to control (11.219.8 mL/m2, p0.03). The 3 groups did not differ in changes
in LVESV, LV mass and had similar rates of clinical events.
Conclusions: Intracoronary infusion of PBMCs and BMMC following AMI does not
improve recovery of myocardial function in the HEBE trial at 2-years of follow-up. The
increase in LVEDV was lower in the BMMC group, suggesting a long-term beneficial
effect on adverse LV remodeling after AMI.
Bone
Marrow
Group
Peripheral
Blood Group
Control
Group
Bone
Marrow
vs.
control
Peripheral
Blood vs.
control
(n59) (n48) (n58) p-value p-value
Primary endpoint (%)
Dysfunctional
segments at baseline
53.319.6 57.519.6 56.218.4
Dysfunctional
segments that
improved during
follow-up
45.026.3 42.520.7 52.322.6 0.14 0.03
LV ejection fraction
(%)
Baseline 43.79.0 41.79.1 42.48.3
24 months 49.28.1 44.910.3 47.79.4
Change 4.28.6 3.08.3 4.08.6 0.58 0.33
LV end-diastolic
volume (mL/m2)
Baseline 97.314.0 98.015.4 100.016.9
24 months 99.920.2 108.028.1 110.328.3
Change 3.516.9 9.220.9 11.219.8 0.03 0.63
LV end-systolic
volume (mL/m2)
Baseline 55.414.5 57.815.9 58.115.1
24 months 51.817.4 61.326.4 59.123.8
Change 1.815.0 3.318.8 3.016.3 0.11 0.94
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Background: Recovery of stunned myocardium can occur within 1 month from the
onset of ST-elevation myocardial infarction (STEMI). We examined the predictors of
recovery from stunning in the INFUSE-AMI randomized trial.
Methods: INFUSE-AMI was a 22 factorial design trial in which patients with STEMI
and proximal or mid left anterior descending (LAD) coronary artery occlusion receiving
bivalirudin anticoagulation were randomized to (1) bolus intracoronary abciximab via the
ClearWay RX catheter vs. no abciximab and (2) manual aspiration with the Export
catheter vs. no aspiration. In a formal substudy MRI imaging at both 5 and 30 days was
performed in 174 patients. MRI analysis included 1) microvascular obstruction (MVO)
defined as a black area inside a zone of delayed enhancement, 2) infarction area, 3)
transmural extent of infarction, and 4) total stunning/remodelling score as a sum of
segmental functional change ()from 5 to 30 days (2marked recovery, 1mild
recovery, 0no change, 1worse).
Results: Overall, left ventricular ejection fraction (LVEF) increased by 2.37.0% from
5 to 30 days. Compared to pts with LVEFmedian (2.1%), pts with LVEFmedian
were older, more often female, and more often diabetic (Table). Both MVO as % of LV
mass and transmural extent of infarction trended lower in pts with better LV recovery.
Multivariable analysis indicated that the independent predictors of better LV recovery
were smaller % MVO (coefficient 0.53, p0.002) and female gender (coefficient 2.68,
p0.05).
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